Biodesix Enhances Access to Nodify Lung® Testing with Launch of New Blood Draw Method
Biodesix announced today the validation and launch of a new method of collecting blood specimens for Nodify Lung Nodule Risk Assessment testing.
×
254 Results
Biodesix announced today the validation and launch of a new method of collecting blood specimens for Nodify Lung Nodule Risk Assessment testing.
Biodesix announced Scott Hutton, CEO, will participate in two upcoming investor conferences: Canaccord Genuity Medtech, Diagnostics, Digital Health & Services Forum and Piper Sandler 35th Annual Healthcare Conference
Biodesix Inc. announced its financial and operating results for the third quarter ended September 30, 2023 and provided a corporate update.
Biodesix announced today that it will release financial results for the third quarter ended September 30, 2023 after the close of trading on Tuesday, November 7.
Discover key insights from Biodesix at CHEST 2023 on Nodify Lung® tests, impacting pulmonary nodule management and reducing invasive procedures.
Biodesix reveals key NSCLC proteomic test data at IASLC 2023, highlighting VeriStrat's predictive power and the Risk of Recurrence test's precision
Scott Hutton, Chief Executive Officer of Biodesix, will participate in two upcoming investor conferences: Morgan Stanley 21st Annual Global Healthcare Conference and H.C. Wainwright 25th Annual Global Investment Conference.
Biodesix reveals ORACLE study results: Nodify XL2 test effectively identifies benign lung nodules, leading to a 51% increase in lung cancer diagnosis rates and fewer invasive procedures.
Biodesix Q2 2023: Core Lung Diagnostic revenue at $11.4M (up 58% YoY), 73% profit margin. 2023 guidance: $52-55M. $27.5M private shares sold.
Biodesix CEO to present at Canaccord Genuity's 43rd Annual Growth Conference on Aug 9, 2023. Discover data-driven lung disease solutions at Biodesix.com.